Balasa Dinverno & Foltz’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $3.68M | Sell |
84,074
-707
| -0.8% | -$34.4K | 0.23% | 43 |
|
|
2022
Q2 | $4.45M | Sell |
84,781
-4,885
| -5% | -$249K | 0.28% | 37 |
|
|
2022
Q1 | $4.64M | Buy |
89,666
+10,963
| +14% | +$569K | 0.31% | 34 |
|
|
2021
Q4 | $4.65M | Sell |
78,703
-1,526
| -2% | -$75.6K | 0.3% | 37 |
|
|
2021
Q3 | $3.45M | Buy |
80,229
+9,446
| +13% | +$418K | 0.24% | 39 |
|
|
2021
Q2 | $2.77M | Buy |
70,783
+15,199
| +27% | +$591K | 0.2% | 51 |
|
|
2021
Q1 | $2.01M | Sell |
55,584
-2,967
| -5% | -$105K | 0.16% | 64 |
|
|
2020
Q4 | $2.15M | Buy |
58,551
+2,687
| +5% | +$98.6K | 0.18% | 52 |
|
|
2020
Q3 | $1.95M | Buy |
55,864
+19,078
| +52% | +$669K | 0.18% | 50 |
|
|
2020
Q2 | $1.14M | Buy |
36,786
+3,158
| +9% | +$107K | 0.13% | 73 |
|
|
2020
Q1 | $1.04M | Sell |
33,628
-5,329
| -14% | -$182K | 0.13% | 79 |
|
|
2019
Q4 | $1.45M | Sell |
38,957
-14,149
| -27% | -$504K | 0.15% | 64 |
|
|
2019
Q3 | $1.81M | Sell |
53,106
-15,563
| -23% | -$566K | 0.21% | 50 |
|
|
2019
Q2 | $2.82M | Sell |
68,669
-8,019
| -10% | -$318K | 0.33% | 27 |
|
|
2019
Q1 | $3.09M | Sell |
76,688
-4,805
| -6% | -$192K | 0.37% | 22 |
|
|
2018
Q4 | $3.38M | Buy |
81,493
+10,857
| +15% | +$451K | 0.42% | 20 |
|
|
2018
Q3 | $2.95M | Buy |
70,636
+4,546
| +7% | +$175K | 0.33% | 25 |
|
|
2018
Q2 | $2.27M | Buy |
66,090
+15,277
| +30% | +$522K | 0.33% | 27 |
|
|
2018
Q1 | $1.71M | Buy |
50,813
+3,942
| +8% | +$136K | 0.26% | 34 |
|
|
2017
Q4 | $1.61M | Buy |
46,871
+4,867
| +12% | +$166K | 0.24% | 42 |
|
|
2017
Q3 | $1.42M | Buy |
42,004
+3,607
| +9% | +$116K | 0.22% | 42 |
|
|
2017
Q2 | $1.22M | Buy |
38,397
+618
| +2% | +$19.5K | 0.2% | 41 |
|
|
2017
Q1 | $1.23M | Sell |
37,779
-1,409
| -4% | -$44.4K | 0.21% | 39 |
|
|
2016
Q4 | $1.21M | Buy |
39,188
+4,653
| +13% | +$142K | 0.21% | 43 |
|
|
2016
Q3 | $1.11M | Buy |
34,535
+974
| +3% | +$32.6K | 0.2% | 44 |
|
|
2016
Q2 | $1.12M | Sell |
33,561
-721
| -2% | -$23K | 0.2% | 40 |
|
|
2016
Q1 | $964K | Sell |
34,282
-3,085
| -8% | -$88.1K | 0.17% | 40 |
|
|
2015
Q4 | $1.14M | Buy |
37,367
+450
| +1% | +$14.2K | 0.19% | 39 |
|
|
2015
Q3 | $1.1M | Buy |
36,917
+305
| +0.8% | +$9.78K | 0.19% | 37 |
|
|
2015
Q2 | $1.17M | Sell |
36,612
-2,646
| -7% | -$86.2K | 0.19% | 34 |
|
|
2015
Q1 | $1.3M | Sell |
39,258
-923
| -2% | -$29.3K | 0.19% | 33 |
|
|
2014
Q4 | $1.19M | Sell |
40,181
-356
| -0.9% | -$10.2K | 0.17% | 40 |
|
|
2014
Q3 | $1.14M | Buy |
40,537
+2,052
| +5% | +$57.6K | 0.17% | 36 |
|
|
2014
Q2 | $1.08M | Sell |
38,485
-983
| -2% | -$28K | 0.12% | 32 |
|
|
2014
Q1 | $1.2M | Buy |
39,468
+1,079
| +3% | +$32.2K | 0.15% | 29 |
|
|
2013
Q4 | $1.12M | Buy |
38,389
+3
| +0% | +$87 | 0.15% | 29 |
|
|
2013
Q3 | $1.05M | Sell |
38,386
-767
| -2% | -$20.9K | 0.17% | 27 |
|
|
2013
Q2 | $1.04M | Buy |
+39,153
| New | +$1.08M | 0.19% | 26 |
|
Other funds holding PFE
Balasa Dinverno & Foltz's PFE Position: Q3 2022 in Review
Balasa Dinverno & Foltz reduced its Pfizer (PFE) stake by 0.83% in Q3 2022, selling an estimated $34.4K and leaving 84,074 shares worth $3.68M. The position accounts for 0.23% of the portfolio, ranked #43.
Balasa Dinverno & Foltz first reported a position in PFE in Q2 2013 and has held it in 38 quarters since. The position peaked at $4.65M in Q4 2021. 3,085 funds tracked by Wall St. Rank hold PFE as of Q3 2022.
- Balasa Dinverno & Foltz held 84,074 shares of Pfizer worth $3.68M as of Q3 2022.
- Balasa Dinverno & Foltz sold 707 Pfizer shares in Q3 2022, an estimated $34.4K.
- Pfizer made up 0.23% of Balasa Dinverno & Foltz's portfolio in Q3 2022, its #43 holding.
- Balasa Dinverno & Foltz first reported a position in Pfizer in Q2 2013 and has held it in 38 quarters since.
- Balasa Dinverno & Foltz's Pfizer position peaked at $4.65M in Q4 2021.
- 3,085 funds tracked by Wall St. Rank held Pfizer as of Q3 2022.
Based on Balasa Dinverno & Foltz's 13F filing for Q3 2022, filed 25 Oct 2022.